Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Spratt

Showing results (261-270 of 498) with videos related to

Pageof 50
Sort By:
Neoplasia (New York, N.Y.)|July 6, 2019
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate CancerJae-Seung Chung, Yugang Wang, James Henderson, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
European Urology Oncology|May 11, 2024
Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data SetRandy A Vince, Helen Sun, Udit Singhal, et al.
JCO Precision Oncology|August 25, 2020
Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate CancerJonathan C Hu, Jeffrey J Tosoian, Ji Qi, et al.
Prostate Cancer and Prostatic Diseases|August 17, 2021
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trialsTommy Jiang, Daniela Markovic, Jay Patel, et al.
BMC Cancer|May 5, 2022
Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancerVipulkumar Dadhania, Daniel Gonzalez, Mustafa Yousif, et al.
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
Neuro-Oncology|May 24, 2019
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastomaShuang G Zhao, Menggang Yu, Daniel E Spratt, et al.
Advances in Radiation Oncology|July 26, 2017
Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancerRafael Gadia, Elton Trigo Teixeira Leite, Ana Luiza Bierrenbach, et al.
European Urology Oncology|August 7, 2022
Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and MetaregressionMichael Baboudjian, Alberto Breda, Pawel Rajwa, et al.
Pageof 50

Showing results (261-270 of 498) with videos related to

Sort By:
Pageof 50
Neoplasia (New York, N.Y.)|July 6, 2019
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate CancerJae-Seung Chung, Yugang Wang, James Henderson, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
European Urology Oncology|May 11, 2024
Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data SetRandy A Vince, Helen Sun, Udit Singhal, et al.
JCO Precision Oncology|August 25, 2020
Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate CancerJonathan C Hu, Jeffrey J Tosoian, Ji Qi, et al.
Prostate Cancer and Prostatic Diseases|August 17, 2021
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trialsTommy Jiang, Daniela Markovic, Jay Patel, et al.
BMC Cancer|May 5, 2022
Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancerVipulkumar Dadhania, Daniel Gonzalez, Mustafa Yousif, et al.
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
Neuro-Oncology|May 24, 2019
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastomaShuang G Zhao, Menggang Yu, Daniel E Spratt, et al.
Advances in Radiation Oncology|July 26, 2017
Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancerRafael Gadia, Elton Trigo Teixeira Leite, Ana Luiza Bierrenbach, et al.
European Urology Oncology|August 7, 2022
Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and MetaregressionMichael Baboudjian, Alberto Breda, Pawel Rajwa, et al.
Pageof 50